Novartis’s Zykadia ASCENDs First-Line NSCLC Heights But Roche’s Alecensa Gives Chase
Executive Summary
Novartis’s anticancer Zykadia is catching up its rival, Pfizer’s Xalkori, by showing a benefit when used first line in the Phase III ASCEND-4 study in NSCLC, but must still look over its shoulder at Roche’s Alecensa.
You may also be interested in...
Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation
The latest drug development news and highlights from our FDA Performance Tracker.
First-Line Japan Alecensa Trial Stopped Early On Benefits
A Japanese Phase III trial investigating the first-line use of Chugai Pharmaceutical Co. Ltd's alectinib in lung cancer has been halted early following better than expected positive results, boding well for the ALK inhibitor in this important setting.
Waiting Game For Minerva After Roluperidone US Filing
The firm’s potential new therapy for the negative symptoms of schizophrenia is now in the hands of the US Food and Drug Administration – some have concerns over whether the supporting data will be enough.